Mission and technology
APCure is a company developing active, specific, Immunotherapy products based on BacVac, a highly innovative technology that uses a live, harmless, bioengineered bacterial vector.
This unique technology was ideated, developed and patented by the TheREx academic laboratory in Grenoble (France), under the lead of Pr B. Polack and Pr. B. Toussaint. Using this technology, APCure will generate new products for the treatment of many types of tumors and infectious diseases, aiming to become a leading developer of active immunotherapy products.
LTvax, the first BacVac-based product
LTvax, the first BacVac-based product, was designed to teach the patient immune system to detect and destroy tumor cells expressing the Large-T protein of the Merkel Cell Polyomavirus, a recently discovered oncovirus that plays a key role in the induction of several cancers, including the Merkel Cell Carcinoma.
LTvax will be used for the treatment of these cancer patients and will respond to a strong medical need: Merkel cell carcinoma is a rare cutaneous cancer with fast progression, high mortality rate and no treatment available.
APCure was founded in March 2012 by the joined forces of AltraBio SAS, a bioinformatics company located in Lyon (France), and the TheREx laboratory.
The name of the company stands for "Antigen Presenting Cells Curation" : Antigen Presenting Cells (APC), conductors of the immune response, are the cells tageted by the BacVac vector following inoculation into the patient.